hydroxyurea and Blood Clot studies

Research Excerpts

Excerpt	Relevance	Reference
"Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited."	9.19	Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014)
"Hydroxyurea is the standard treatment in high-risk patients with polycythemia vera."	9.01	Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. ( Barbui, T; Carobbio, A; De Stefano, V; Ferrari, A; Finazzi, G; Ghirardi, A; Masciulli, A; Vannucchi, AM, 2019)
"Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown."	8.12	Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. ( Alvarez-Larrán, A; Angona, A; Arellano-Rodrigo, E; Ayala, R; Bellosillo, B; Caballero, G; Carreño-Tarragona, G; Cuevas, B; Del Orbe-Barreto, R; Ferrer-Marín, F; Fox, ML; García, R; García-Gutiérrez, V; García-Hernández, C; Garrote, M; Gasior, M; Gómez, M; Gómez-Casares, MT; Guerrero, L; Hernández-Boluda, JC; Magro, E; Martínez, CM; Mata-Vazquez, MI; Murillo, I; Pereira, A; Pérez-Encinas, M; Pérez-López, R; Ramírez, MJ; Raya, JM; Xicoy, B, 2022)
"ABSTRACTBackground: Current guidelines recommend hydroxyurea (HU) as frontline therapy for patients with high-risk essential thrombocythemia (ET) to prevent thrombosis."	7.91	Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. ( Davidoff, AJ; Giri, S; Gore, SD; Huntington, SF; Ma, X; Podoltsev, NA; Wang, R; Wang, X; Zeidan, AM; Zhu, M, 2019)
"Hydroxyurea (HU) resistance or intolerance occurs in 15 to 24% of patients with polycythemia vera (PV)."	7.91	Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis. ( Delforge, M; Demuynck, T; Devos, T; Vandenberghe, P; Verhoef, G, 2019)
"Thrombotic events and disease progression were infrequent in both arms, whereas grade 3/4 adverse events were more frequent with PEG (46% vs 28%)."	7.11	A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. ( Arango Ossa, JE; Arcasoy, MO; Bacigalupo, A; Barbui, T; Berenzon, D; Catchatourian, R; De Stefano, V; Dueck, AC; Ewing, J; Farnoud, N; Goldberg, JD; Harrison, CN; Hoffman, R; Kessler, CM; Kiladjian, JJ; Kosiorek, HE; Kremyanskaya, M; Leibowitz, DS; Levine, MF; Marchioli, R; Mascarenhas, J; McGovern, E; McMullin, MF; Mead, AJ; Mesa, RA; Nagler, A; Najfeld, V; O'Connell, CL; Penson, AV; Prchal, JT; Price, L; Rambaldi, A; Rampal, RK; Rondelli, D; Salama, ME; Sandy, L; Silver, RT; Tognoni, G; Tripodi, J; Vannucchi, AM; Weinberg, RS; Winton, EF; Yacoub, A, 2022)
"Polycythemia vera is a Philadelphia negative myeloproliferative neoplasm characterized by erythrocytosis in which the major cause of morbidity and mortality is thrombosis."	5.62	Management of hydroxyurea resistant or intolerant polycythemia vera. ( Pasricha, SR; Prince, HM; Raman, I; Yannakou, CK, 2021)
"Hydroxyurea is an effective agent in the treatment of PV, but continued assessment of its mutagenic potential is necessary."	5.27	Treatment of polycythemia vera with hydroxyurea. ( Berk, PD; Donovan, PB; Goldberg, JD; Kaplan, ME; Knospe, WH; Laszlo, J; Mack, K; Najean, Y; Silberstein, EB; Tatarsky, I, 1984)
"Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited."	5.19	Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014)
"We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group)."	5.17	Cardiovascular events and intensity of treatment in polycythemia vera. ( Angelucci, E; Barbui, T; Cacciola, R; Cascavilla, N; Cavazzina, R; Cilloni, D; De Stefano, V; Elli, E; Finazzi, G; Iurlo, A; Latagliata, R; Lunghi, F; Lunghi, M; Marchioli, R; Marfisi, RM; Masciulli, A; Musolino, C; Musto, P; Quarta, G; Randi, ML; Rapezzi, D; Ruggeri, M; Rumi, E; Santini, S; Scarano, M; Scortechini, AR; Siragusa, S; Spadea, A; Specchia, G; Tieghi, A; Vannucchi, AM; Visani, G, 2013)
" As compared with hydroxyurea plus aspirin, anagrelide plus aspirin was associated with increased rates of arterial thrombosis (P=0."	5.11	Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. ( Bareford, D; Buck, G; Campbell, PJ; East, CL; Green, AR; Grigg, AP; Harrison, CN; Reilly, JT; Revell, P; van der Walt, JD; Wheatley, K; Wilkins, BS; Woodcock, BE, 2005)
"We have previously demonstrated that hydroxyurea (HU) reduces the rate of vascular complications in patients with essential thrombocythaemia (ET) at high risk of thrombosis."	5.09	Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. ( Barbui, T; Finazzi, G; Rodeghiero, F; Ruggeri, M, 2000)
"Hydroxyurea is the standard treatment in high-risk patients with polycythemia vera."	5.01	Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. ( Barbui, T; Carobbio, A; De Stefano, V; Ferrari, A; Finazzi, G; Ghirardi, A; Masciulli, A; Vannucchi, AM, 2019)
" The aim of this study was to meta-analyze currently available data comparing anagrelide to hydroxyurea for reduction of rates of thrombosis, bleeding and death among patients with ET."	4.91	Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis. ( Chai-Adisaksopha, C; Garcia, D; Samuelson, B, 2015)
" An algorithm for the treatment of patients with erythremia is proposed along with recommendations on the use of aspirin, hydroxyurea, alpha-interpheron, and imatinib."	4.88	[True polycythemia: current views of pathogenesis, diagnostics and treatment]. ( Bakhteeva, TD; Kalinkina, NV; Skliannaia, EV; Taradin, GG; Vatutin, NT, 2012)
" Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P."	4.80	Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998)
" Treatment selection is based on a patient's age and a history of thrombosis in patients with low-risk PV treated with therapeutic phlebotomy and aspirin alone, whereas cytoreductive therapy with either hydroxyurea or interferon alfa (IFN-α) is added for high-risk disease."	4.31	Moving toward disease modification in polycythemia vera. ( Bewersdorf, JP; Bose, P; How, J; Masarova, L; Mascarenhas, J; Pemmaraju, N; Rampal, RK, 2023)
"Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown."	4.12	Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. ( Alvarez-Larrán, A; Angona, A; Arellano-Rodrigo, E; Ayala, R; Bellosillo, B; Caballero, G; Carreño-Tarragona, G; Cuevas, B; Del Orbe-Barreto, R; Ferrer-Marín, F; Fox, ML; García, R; García-Gutiérrez, V; García-Hernández, C; Garrote, M; Gasior, M; Gómez, M; Gómez-Casares, MT; Guerrero, L; Hernández-Boluda, JC; Magro, E; Martínez, CM; Mata-Vazquez, MI; Murillo, I; Pereira, A; Pérez-Encinas, M; Pérez-López, R; Ramírez, MJ; Raya, JM; Xicoy, B, 2022)
"ABSTRACTBackground: Current guidelines recommend hydroxyurea (HU) as frontline therapy for patients with high-risk essential thrombocythemia (ET) to prevent thrombosis."	3.91	Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. ( Davidoff, AJ; Giri, S; Gore, SD; Huntington, SF; Ma, X; Podoltsev, NA; Wang, R; Wang, X; Zeidan, AM; Zhu, M, 2019)
"Hydroxyurea (HU) resistance or intolerance occurs in 15 to 24% of patients with polycythemia vera (PV)."	3.91	Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis. ( Delforge, M; Demuynck, T; Devos, T; Vandenberghe, P; Verhoef, G, 2019)
"Pegylated interferon (peg-IFN) was proven by phase II trials to be effective in polycythemia vera (PV); however, it is not clear whether it could improve patient outcome compared to hydroxyurea (HU)."	3.85	Can pegylated interferon improve the outcome of polycythemia vera patients? ( Beggiato, E; Benevolo, G; Boccadoro, M; Borchiellini, A; Cerrano, M; Crisà, E; Ferrero, D; Lanzarone, G; Manzini, PM; Riera, L, 2017)
" Post-2005 diagnosed patients were also more or less likely to receive aspirin and cytoreductive therapy, respectively, and, despite their older age distribution, displayed significantly lower risk of thrombosis in high risk disease."	3.81	Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. ( Barbui, T; Carobbio, A; Finazzi, G; Gisslinger, H; Pardanani, A; Passamonti, F; Pieri, L; Rambaldi, A; Randi, ML; Rodeghiero, F; Rumi, E; Tefferi, A; Thiele, J; Vannucchi, AM, 2015)
"Patients in the interferon alpha 2 b group achieved higher rates of hematologic and molecular remission than patients in the hydroxyurea group, with a lower incidence of thrombosis."	3.80	Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis. ( Duan, YC; Zhang, ZR, 2014)
"This study was designed to compare the oxidative stress parameters of patients with polycythemia vera (PV) to those of healthy volunteers and to investigate the probable relationship between vascular events and parameters of oxidative status such as total oxidative status (TOS), total antioxidant status, oxidative stress index (OSI) and malondialdehyde (MDA) in PV patients."	3.80	The thrombotic events in polycythemia vera patients may be related to increased oxidative stress. ( Akalin, I; Alver, A; Durmus, A; Mentese, A; Sumer, A; Topal, C; Yilmaz, M, 2014)
"Thrombotic events and disease progression were infrequent in both arms, whereas grade 3/4 adverse events were more frequent with PEG (46% vs 28%)."	3.11	A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. ( Arango Ossa, JE; Arcasoy, MO; Bacigalupo, A; Barbui, T; Berenzon, D; Catchatourian, R; De Stefano, V; Dueck, AC; Ewing, J; Farnoud, N; Goldberg, JD; Harrison, CN; Hoffman, R; Kessler, CM; Kiladjian, JJ; Kosiorek, HE; Kremyanskaya, M; Leibowitz, DS; Levine, MF; Marchioli, R; Mascarenhas, J; McGovern, E; McMullin, MF; Mead, AJ; Mesa, RA; Nagler, A; Najfeld, V; O'Connell, CL; Penson, AV; Prchal, JT; Price, L; Rambaldi, A; Rampal, RK; Rondelli, D; Salama, ME; Sandy, L; Silver, RT; Tognoni, G; Tripodi, J; Vannucchi, AM; Weinberg, RS; Winton, EF; Yacoub, A, 2022)
"Hydroxyurea (HU) was started at diagnosis in 32 "symptomatic" patients and in 33 patients aged >70 years."	2.74	Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results. ( Alimena, G; Biondo, F; Breccia, M; Carmosino, I; Fama, A; Latagliata, R; Mazzucconi, MG; Napoleone, L; Petti, MC; Rago, A; Santoro, C; Spadea, A; Stefanizzi, C; Volpicelli, P; Vozella, F, 2009)
"Essential thrombocythemia is associated with an increased risk of thromboembolic complications."	2.74	The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia. ( Chojnowski, K; Robak, T; Smolewski, P; Treliński, J; Tybura, M, 2009)
"Treatment with busulfan or interferon-α is usually effective in hydroxyurea failures."	2.48	Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. ( Tefferi, A, 2012)
"Treatment with hydroxyurea is usually considered for patients with recurrent vaso-occlusive events, but additional indications for treatment may include laboratory markers of disease severity and evidence of chronic organ dysfunction."	2.45	Advances in the use of hydroxyurea. ( Aygun, B; Ware, RE, 2009)
"The risk of major thrombosis is higher in patients with ET who are older than 60 years and who have had a previous occlusive event."	2.42	Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia. ( Barbui, T; Finazzi, G, 2003)
"Hydroxyurea (HU) has a limited, if any, leukemogenic potential and should be considered the current cytotoxic drug for patients at high risk for thrombotic complications, ie, those with age above 60 years or previous thrombotic events."	2.42	The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? ( Barbui, T, 2004)
" Anagrelide offers the advantage of oral dosing and long-term effectiveness at managing platelet counts."	2.42	Indications for lowering platelet numbers in essential thrombocythemia. ( Barbui, T, 2003)
"Major bleeding is rare and seem to be related to higher platelet counts: therefore, a platelet count over 1500 x 10(9)/L is generally regarded as an indication for cytoreduction."	2.39	Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. ( Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ, 1996)
"Within the 1258 SMF of the MYSEC (MYelofibrosis SECondary to PV and ET) dataset, 135 (10."	1.72	Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients. ( Albano, F; Arcaini, L; Auteri, G; Barbui, T; Benevolo, G; Bertù, L; Brociner, M; Caramazza, D; Caramella, M; Casetti, IC; Cattaneo, D; Cervantes, F; De Stefano, V; Della Porta, MG; Devos, T; Gotlib, J; Guglielmelli, P; Iurlo, A; Kiladjian, JJ; Komrokji, RS; Kuykendall, A; Maffioli, M; Merli, M; Mora, B; Palandri, F; Passamonti, F; Ross, DM; Rotunno, G; Ruggeri, M; Rumi, E; Salmoiraghi, S; Silver, RT; Vannucchi, AM, 2022)
"Polycythemia vera is a Philadelphia negative myeloproliferative neoplasm characterized by erythrocytosis in which the major cause of morbidity and mortality is thrombosis."	1.62	Management of hydroxyurea resistant or intolerant polycythemia vera. ( Pasricha, SR; Prince, HM; Raman, I; Yannakou, CK, 2021)
"Risk of thrombosis is higher in JAK2-mutated ET."	1.51	Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019)
"We recorded 348 recurrences (venous in 142 cases) over 6075 patient-years, with an incidence rate of 5."	1.48	Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. ( Barbui, T; Betti, S; Carobbio, A; De Stefano, V; Finazzi, G; Ghirardi, A; Rossi, E; Vannucchi, AM, 2018)
"Hydroxyurea was the most commonly used cytoreductive therapy."	1.46	Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. ( Bilgir, O; Çağlıyan, G; Çekdemir, D; Cömert, M; Haznedaroğlu, İC; İlhan, O; Kaya, E; Özdemirkıran, F; Şahin, F; Saydam, G; Soyer, N; Ünal, A; Vural, F; Yılmaz, M, 2017)
"Cyclical thrombocytosis was documented in 29 patients (15%), the majority of whom were receiving hydroxyurea."	1.40	Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea. ( Forsyth, C; Grigg, A; Verner, E, 2014)
"Previous thrombosis is an established risk factor for rethrombosis in patients with ET."	1.38	Cerebral infarct in a patient with a history of systemic arterial and venous thrombosis from essential thrombocythemia. ( Cho, KH; Kim, KT; Sohn, SI, 2012)
"Mechanical valve thrombosis is a rare condition in an adequately anticoagulated patient in the absence of underlying thrombophilia."	1.37	Anticoagulant-resistant thrombophilia in a patient with polycythemia vera: a case report. ( Cherian, SV; Das, S; Gajra, A; Garcha, AS; Jasti, S; Karachiwala, H, 2011)
"Aortic thrombus formation is rare in the patients with essential thrombocytosis (ET); therefore, no guidelines for its management have been established."	1.31	Medical management of a large aortic thrombus in a young woman with essential thrombocythemia. ( Agha, S; Cleary, JP; Fang, M; Lee, R; Lockridge, L; Mazur, EM, 2001)
"However, thrombosis is not sufficiently predictable with standard diagnostic procedures."	1.30	APC resistance as an additional thrombotic risk factor in a patient suffering from polycythemia vera and recurrent thrombosis. ( Heidtmann, HH; Lamparter, S; Schuermann, M, 1997)
"Hydroxyurea is an effective agent in the treatment of PV, but continued assessment of its mutagenic potential is necessary."	1.27	Treatment of polycythemia vera with hydroxyurea. ( Berk, PD; Donovan, PB; Goldberg, JD; Kaplan, ME; Knospe, WH; Laszlo, J; Mack, K; Najean, Y; Silberstein, EB; Tatarsky, I, 1984)

Research

Studies (108)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Change in the Total Symptom Score (TSS)

Timeframe	Studies, this research(%)	All Research%
pre-1990	5 (4.63)	18.7374
1990's	13 (12.04)	18.2507
2000's	24 (22.22)	29.6817
2010's	53 (49.07)	24.3611
2020's	13 (12.04)	2.80

Authors	Studies
Michalak, J	1
Simman, R	1
Oostra, D	1
Mascarenhas, J	2
Kosiorek, HE	1
Prchal, JT	2
Rambaldi, A	2
Berenzon, D	1
Yacoub, A	1
Harrison, CN	5
McMullin, MF	3
Vannucchi, AM	9
Ewing, J	1
O'Connell, CL	1
Kiladjian, JJ	6
Mead, AJ	1
Winton, EF	1
Leibowitz, DS	1
De Stefano, V	6
Arcasoy, MO	1
Kessler, CM	1
Catchatourian, R	1
Rondelli, D	1
Silver, RT	2
Bacigalupo, A	1
Nagler, A	1
Kremyanskaya, M	1
Levine, MF	1
Arango Ossa, JE	1
McGovern, E	1
Sandy, L	1
Salama, ME	1
Najfeld, V	1
Tripodi, J	1
Farnoud, N	1
Penson, AV	1
Weinberg, RS	1
Price, L	1
Goldberg, JD	4
Barbui, T	22
Marchioli, R	3
Tognoni, G	1
Rampal, RK	2
Mesa, RA	3
Dueck, AC	1
Hoffman, R	1
Alvarez-Larrán, A	5
Garrote, M	1
Ferrer-Marín, F	3
Pérez-Encinas, M	2
Mata-Vazquez, MI	1
Bellosillo, B	3
Arellano-Rodrigo, E	2
Gómez, M	4
García, R	1
García-Gutiérrez, V	2
Gasior, M	1
Cuevas, B	2
Angona, A	3
Gómez-Casares, MT	3
Martínez, CM	1
Magro, E	2
Ayala, R	1
Del Orbe-Barreto, R	1
Pérez-López, R	1
Fox, ML	2
Raya, JM	2
Guerrero, L	1
García-Hernández, C	1
Caballero, G	1
Murillo, I	1
Xicoy, B	2
Ramírez, MJ	2
Carreño-Tarragona, G	1
Hernández-Boluda, JC	4
Pereira, A	1
Mora, B	3
Guglielmelli, P	1
Kuykendall, A	1
Rumi, E	3
Maffioli, M	2
Palandri, F	1
Caramella, M	1
Salmoiraghi, S	1
Gotlib, J	2
Iurlo, A	2
Cervantes, F	2
Ruggeri, M	5
Albano, F	1
Benevolo, G	2
Ross, DM	2
Della Porta, MG	1
Devos, T	2
Rotunno, G	1
Komrokji, RS	1
Casetti, IC	1
Merli, M	1
Brociner, M	1
Caramazza, D	2
Auteri, G	1
Cattaneo, D	1
Bertù, L	1
Arcaini, L	1
Passamonti, F	4
Chen, J	1
Dong, H	2
Fu, R	2
Liu, X	2
Xue, F	2
Liu, W	2
Chen, Y	2
Sun, T	2
Ju, M	2
Dai, X	2
Li, H	1
Wang, W	1
Chi, Y	1
Yang, R	2
Zhang, L	3
Zhang, D	1
Zhou, H	1
Zhang, X	1
Huang, Y	1
Bewersdorf, JP	2
How, J	1
Masarova, L	1
Bose, P	1
Pemmaraju, N	1
Kellner, A	1
Dombi, P	2
Illes, A	2
Demeter, J	2
Homor, L	2
Ercsei, I	1
Simon, Z	2
Karadi, E	2
Herczeg, J	1
Gy Korom, V	1
Gasztonyi, Z	1
Szerafin, L	1
Udvardy, M	2
Egyed, M	2
Zeidan, AM	2
Edahiro, Y	1
Okada, Y	1
Kimura, F	1
Raman, I	1
Pasricha, SR	1
Prince, HM	1
Yannakou, CK	1
Na, J	1
Choi, SY	1
Baek, S	1
Lee, H	1
Godfrey, AL	1
Campbell, PJ	3
MacLean, C	1
Buck, G	3
Cook, J	1
Temple, J	1
Wilkins, BS	3
Wheatley, K	3
Nangalia, J	1
Grinfeld, J	1
Forsyth, C	3
Green, AR	3
Guy, A	1
Gourdou-Latyszenok, V	1
Le Lay, N	1
Peghaire, C	1
Kilani, B	1
Dias, JV	1
Duplaa, C	1
Renault, MA	1
Denis, C	1
Villeval, JL	1
Boulaftali, Y	1
Jandrot-Perrus, M	1
Couffinhal, T	1
James, C	1
Tefferi, A	8
Azevedo, AP	1
Silva, SN	1
Reichert, A	1
Lima, F	1
Júnior, E	1
Rueff, J	1
Rossi, E	1
Carobbio, A	3
Ghirardi, A	3
Betti, S	1
Finazzi, G	12
Masciulli, A	3
Sankar, K	1
Stein, BL	2
Al-Sawaf, O	1
Köhler, P	1
Eichenauer, DA	1
Böll, B	1
Kochanek, M	1
Shimabukuro-Vornhagen, A	1
Griesshammer, M	1
Besses, C	4
Podoltsev, NA	1
Zhu, M	1
Wang, R	1
Wang, X	1
Davidoff, AJ	1
Huntington, SF	1
Giri, S	1
Gore, SD	1
Ma, X	1
Demuynck, T	1
Verhoef, G	1
Delforge, M	1
Vandenberghe, P	1
Ferrari, A	1
Leone, G	1
Gordeuk, VR	1
Spivak, JL	2
Verner, E	1
Grigg, A	2
Ahn, IE	1
Natelson, E	1
Rice, L	1
Zhang, ZR	1
Duan, YC	1
Durmus, A	1
Mentese, A	2
Yilmaz, M	2
Sumer, A	1
Akalin, I	1
Topal, C	1
Alver, A	1
Martínez-Avilés, L	2
Antelo, ML	1
Burgaleta, C	2
Mata, MI	2
Martínez-Trillos, A	1
Durán, MA	2
Marcote, B	1
Ancochea, A	1
Senín, A	1
Vicente, V	1
Tantawy, AA	1
Adly, AA	1
Ismail, EA	1
Darwish, YW	1
Ali Zedan, M	1
Thiele, J	1
Gisslinger, H	2
Rodeghiero, F	5
Randi, ML	3
Pieri, L	1
Pardanani, A	1
Lim, Y	1
Lee, JO	1
Kim, SH	1
Kim, JW	1
Kim, YJ	1
Lee, KW	1
Lee, JS	1
Bang, SM	1
Arcasoy, M	1
Nguyen, MH	1
Shah, N	1
Moliterno, A	1
Jamieson, C	1
Pollyea, DA	1
Scott, B	1
Wadleigh, M	1
Levine, R	1
Komrokji, R	1
Klisovic, R	1
Gundabolu, K	1
Kropf, P	1
Wetzler, M	1
Oh, ST	1
Ribeiro, R	1
Paschal, R	1
Mohan, S	1
Podoltsev, N	1
Prchal, J	1
Talpaz, M	1
Snyder, D	1
Verstovsek, S	1
Samuelson, B	1
Chai-Adisaksopha, C	1
Garcia, D	1
Nazha, A	1
Gerds, AT	1
Soyer, N	1
Haznedaroğlu, İC	1
Cömert, M	1
Çekdemir, D	1
Ünal, A	1
Çağlıyan, G	1
Bilgir, O	1
İlhan, O	1
Özdemirkıran, F	1
Kaya, E	1
Şahin, F	1
Vural, F	1
Saydam, G	1
Douglas, G	1
Harrison, C	2
Bennett, M	1
Stevenson, W	1
Hounsell, J	1
Ratnasingam, S	1
Ritchie, D	1
Martínez-López, J	1
Cruz, Y	1
Aragües, P	1
Montesdeoca, S	1
Hernández-Rivas, JA	1
Steegmann, JL	1
Kerguelen, A	1
Bárez, A	1
García, MC	1
Boqué, C	1
Martínez, C	1
Albors, M	1
García, F	1
Crisà, E	1
Cerrano, M	1
Beggiato, E	1
Lanzarone, G	1
Manzini, PM	1
Borchiellini, A	1
Riera, L	1
Boccadoro, M	1
Ferrero, D	1
Varma, S	1
Sharma, A	1
Malhotra, P	1
Kumari, S	1
Jain, S	1
Varma, N	1
Caracciolo, C	1
Barone, R	1
Malato, A	1
Saccullo, G	1
Cigna, V	1
Berretta, S	1
Schinocca, L	1
Quintini, G	1
Abbadessa, V	1
Di Raimondo, F	1
Siragusa, S	2
Bareford, D	2
Erber, WN	1
Wright, P	1
Latagliata, R	2
Rago, A	1
Spadea, A	2
Santoro, C	1
Carmosino, I	1
Breccia, M	1
Napoleone, L	1
Fama, A	1
Biondo, F	1
Volpicelli, P	1
Vozella, F	1
Stefanizzi, C	1
Petti, MC	1
Alimena, G	1
Mazzucconi, MG	2
Treliński, J	1
Tybura, M	1
Smolewski, P	1
Robak, T	1
Chojnowski, K	1
Ware, RE	2
Aygun, B	1
Finotto, S	1
Fortuna, S	1
Weston, H	1
Cowell, V	1
Grimmett, K	1
Saal, R	1
Jones, M	1
Mills, T	1
Gill, D	1
Marlton, P	1
Bird, R	1
Mollee, P	1
Zhang, Z	1
Wan, X	1
Liu, Y	1
Lin, X	1
Ni, Z	1
Yang, X	1
Mannucci, PM	1
Amat, P	1
Navarro, B	1
Teruel, A	1
Martínez-Ruiz, F	1
Sonmez, M	1
Saglam, F	1
Karahan, SC	1
Erkut, N	1
Sonmez, B	1
Ucar, F	1
Topbas, M	1
Ovali, E	1
Chinnakotla, S	1
Klintmalm, GB	1
Kim, P	1
Tomiyama, K	1
Klintmalm, E	1
Davis, GL	1
Trotter, JF	1
Saad, R	1
Landaverde, C	1
Levy, MF	1
Goldstein, RM	1
Stone, MJ	1
Das, S	1
Karachiwala, H	1
Cherian, SV	1
Garcha, AS	1
Jasti, S	1
Gajra, A	1
Tsai, M	1
Kita, A	1
Leach, J	1
Rounsevell, R	1
Huang, JN	1
Moake, J	1
Fletcher, DA	1
Lam, WA	1
Kim, KT	1
Sohn, SI	1
Cho, KH	1
Vatutin, NT	1
Taradin, GG	1
Bakhteeva, TD	1
Kalinkina, NV	1
Skliannaia, EV	1
Specchia, G	1
Cacciola, R	1
Cavazzina, R	1
Cilloni, D	1
Elli, E	1
Lunghi, F	1
Lunghi, M	1
Marfisi, RM	1
Musto, P	1
Musolino, C	1
Cascavilla, N	1
Quarta, G	1
Rapezzi, D	1
Scortechini, AR	1
Santini, S	1
Scarano, M	1
Tieghi, A	1
Angelucci, E	1
Visani, G	1
Barosi, G	1
Grossi, A	2
Gugliotta, L	1
Liberato, LN	1
Marchetti, M	1
Tura, S	1
Elliott, MA	1
East, CL	1
van der Walt, JD	1
Reilly, JT	1
Grigg, AP	1
Revell, P	1
Woodcock, BE	1
Cacciola, RR	1
Di Francesco, E	1
Pezzella, F	1
Tibullo, D	1
Giustolisi, R	1
Cacciola, E	1
Landolfi, R	1
Di Gennaro, L	1
Kelly, SV	1
Burke, RF	1
Lee, KS	1
Torloni, AS	1
Lee, RW	1
Northfelt, D	1
Fonseca, R	1
Donovan, PB	3
Kaplan, ME	2
Tatarsky, I	1
Najean, Y	1
Silberstein, EB	1
Knospe, WH	1
Laszlo, J	1
Mack, K	2
Berk, PD	3
Van Genderen, PJ	2
Michiels, JJ	2
Feiner, RH	1
Ring, T	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)[NCT01259856]	Phase 3	168 participants (Actual)	Interventional	2011-09-30	Completed
Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms[NCT05850273]		50 participants (Anticipated)	Observational	2023-03-16	Recruiting
A Randomised Trial to Compare Aspirin vs Hydroxyurea/Aspirin in 'Intermediate Risk' Primary Thrombocythaemia and Aspirin Only With Observation in 'Low Risk'Primary Thrombocythaemia[NCT00175838]		1,398 participants (Actual)	Interventional	1997-07-31	Completed
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial[NCT03003325]	Phase 2	127 participants (Actual)	Interventional	2017-02-02	Completed
A Large-scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events In Patients With Polycythemia Vera (PV)[NCT01645124]	Phase 3	365 participants (Actual)	Interventional	2008-05-31	Terminated (stopped due to Low accrual rate not allowing planned sample size leads to a futility condition)
Multicenter Phase 2 Study of Efficacy and Safety of Pegylated Interferon-alfa 2a in Polycythemia Vera Patients[NCT00241241]	Phase 2	40 participants	Interventional	2004-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Change in the Total Symptom Score which assessed improvement in disease symptoms measured by the change in TSS from the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) instrument being used in this study from baseline to 12 months. This 19 item instrument includes the previously validated 9 item brief fatigue inventory (BFI), symptoms related to splenomegaly, inactivity, cough, night sweats, pruritus, bone pains, fevers, weight loss, and an overall quality of life assessment. Each item is scored from 0-10 with full scale from 0-190, with higher scores mean worse symptoms. (NCT01259856)
Timeframe: baseline and 12 months

Number of Participants With Major Cardiovascular Events After Therapy

Number of Participants With Complete Remission (CR)

Intervention	score on a scale (Mean)
PEGASYS	1.16
Hydroxyurea	-1.0

Intervention	Participants (Count of Participants)
PEGASYS	1
Hydroxyurea	1

Number of participants with Complete Remission after 12 months of therapy assessed by hematologic response rates two strata of patients with high risk polycythemia vera (PV) or high risk essential thrombocythemia (ET). Complete remission means no evidence of disease. (NCT01259856)
Timeframe: 12 months

Number of Participants With Grade 3 and Grade 4 Hematological and Non-hematological Events

Intervention	Participants (Count of Participants)
	Essential Thrombocythemia	Polycythemia Vera
Hydroxyurea	19	13
PEGASYS	17	12

Number of Participants with Grade 3 and Grade 4 Hematological and Non-hematological Events using the Common Terminology Criteria for Adverse Events (CTCAE) 4.0 to assess the toxicity, safety and tolerability of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea). (NCT01259856)
Timeframe: 4 years

Number of Participants With Partial Remission (PR)

Intervention	Participants (Count of Participants)
	Grade 3 Hematological event	Grade 4 Hematological event	Grade 3 Non-hematological event	Grade 4 Non-hematological event
Hydroxyurea	2	0	14	3
PEGASYS	3	0	27	2

Number of participants with Partial Remission after 12 months of therapy assessed by hematologic response rates two strata of patients with high risk polycythemia vera (PV) or high risk essential thrombocythemia (ET). Partial Remission means decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment. (NCT01259856)
Timeframe: 12 months

Number of Participants With Progression of Disease or Death

Intervention	Participants (Count of Participants)
	Essential Thrombocythemia	Polycythemia Vera
Hydroxyurea	11	17
PEGASYS	10	25

"Survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy~To estimate survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) by capturing the rate of progression to a more advanced myeloid malignancy." (NCT01259856)
Timeframe: 4 years

Article	Year
SOHO State of the Art Updates and Next Questions \| Polycythemia Vera: Is It Time to Rethink Treatment? Clinical lymphoma, myeloma & leukemia, 2023, Volume: 23, Issue:2 Topics: Aspirin; Humans; Hydroxyurea; Janus Kinase 2; Middle Aged; Polycythemia Vera; Primary Myelofibrosis;	2023
Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era. Expert review of hematology, 2020, Volume: 13, Issue:11 Topics: Bone Marrow; Clinical Trials as Topic; Combined Modality Therapy; DNA Methylation; Drugs, Investigat	2020
Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches. Clinical advances in hematology & oncology : H&O, 2017, Volume: 15, Issue:9 Topics: Age Factors; Calreticulin; Female; Hematocrit; Humans; Hydroxyurea; Interferons; Janus Kinase 2; Mal	2017
Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction? Journal of the National Comprehensive Cancer Network : JNCCN, 2018, Volume: 16, Issue:12 Topics: Antineoplastic Agents; Bone Marrow; Cell Proliferation; Evidence-Based Medicine; Hematopoiesis; Huma	2018
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. Haematologica, 2019, Volume: 104, Issue:12 Topics: Hemorrhage; Humans; Hydroxyurea; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Risk Factors;	2019
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. Journal of the National Comprehensive Cancer Network : JNCCN, 2015, Volume: 13, Issue:4 Topics: Antineoplastic Agents; Calreticulin; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; J	2015
Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis. Journal of thrombosis and thrombolysis, 2015, Volume: 40, Issue:4 Topics: Hemorrhage; Humans; Hydroxyurea; Quinazolines; Thrombocythemia, Essential; Thrombosis	2015
Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera? The oncologist, 2016, Volume: 21, Issue:4 Topics: Busulfan; Cell Proliferation; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myeloid, Acute; Nitrile	2016
Advances in the use of hydroxyurea. Hematology. American Society of Hematology. Education Program, 2009 Topics: Adult; Anemia, Sickle Cell; Animals; Arterial Occlusive Diseases; Bone Marrow Diseases; Child; Clini	2009
Do we know more about essential thrombocythemia because of JAK2V617F? Current hematologic malignancy reports, 2009, Volume: 4, Issue:1 Topics: Female; Humans; Hydroxyurea; Janus Kinase 2; Polycythemia Vera; Pregnancy; Pregnancy Complications;	2009
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. American journal of hematology, 2012, Volume: 87, Issue:3 Topics: Acute Disease; Age Factors; Alkylating Agents; Anticoagulants; Aspirin; Busulfan; Disease Management	2012
[True polycythemia: current views of pathogenesis, diagnostics and treatment]. Klinicheskaia meditsina, 2012, Volume: 90, Issue:8 Topics: Age Factors; Algorithms; Antineoplastic Agents; Aspirin; Benzamides; Combined Modality Therapy; Hema	2012
Indications for lowering platelet numbers in essential thrombocythemia. Seminars in hematology, 2003, Volume: 40, Issue:1 Suppl 1 Topics: Age Factors; Drug Therapy, Combination; Humans; Hydroxyurea; Interferon-alpha; Platelet Aggregation	2003
Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia. Current hematology reports, 2003, Volume: 2, Issue:3 Topics: Alkylating Agents; Hemorrhage; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Platelet Count;	2003
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 2004, Volume: 89, Issue:2 Topics: Acute Disease; Adult; Aged; Alkylating Agents; Cell Transformation, Neoplastic; Child; Clinical Tria	2004
The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Seminars in hematology, 2004, Volume: 41, Issue:2 Suppl 3 Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Disease Progression; Female;	2004
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. British journal of haematology, 2005, Volume: 128, Issue:3 Topics: Aged; Aspirin; Hemorrhage; Humans; Hydroxyurea; Middle Aged; Polycythemia Vera; Risk Factors; Thromb	2005
Essential thrombocythemia: scientific advances and current practice. Current opinion in hematology, 2006, Volume: 13, Issue:2 Topics: Antineoplastic Agents; Aspirin; Bone Marrow Examination; Humans; Hydroxyurea; In Situ Hybridization,	2006
Evolving management of essential thrombocythaemia. European journal of haematology. Supplementum, 2007, Issue:68 Topics: Cell Transformation, Neoplastic; Humans; Hydroxyurea; Leukemia; Thrombocythemia, Essential; Thrombos	2007
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. Leukemia & lymphoma, 1996, Volume: 22 Suppl 1 Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; B	1996
[Portal vein thrombosis associated with essential thrombocytosis. Clinical cases and review of the literature]. Revista medica de Chile, 1996, Volume: 124, Issue:3 Topics: Adult; Aged; Diagnosis, Differential; Echocardiography, Doppler; Enteral Nutrition; Female; Humans;	1996
Treatment of essential thrombocythemia with special emphasis on leukemogenic risk. Annals of hematology, 1999, Volume: 78, Issue:9 Topics: Antineoplastic Agents; Humans; Hydroxyurea; Leukemia; Middle Aged; Risk Factors; Thrombocytosis; Thr	1999
Treatment of polycythaemia vera and essential thrombocythaemia. Bailliere's clinical haematology, 1998, Volume: 11, Issue:4 Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In	1998
A clinical update in polycythemia vera and essential thrombocythemia. The American journal of medicine, 2000, Aug-01, Volume: 109, Issue:2 Topics: Age Factors; Carcinogens; Cell Transformation, Neoplastic; Chronic Disease; Enzyme Inhibitors; Femal	2000
Efficacy and safety of hydroxyurea in patients with essential thrombocythemia. Pathologie-biologie, 2001, Volume: 49, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anemia; Cell Transformation, Neoplastic; Cohort Studies; Female; Fol	2001
[Essential thrombocythemia: conventional therapy]. Haematologica, 1991, Volume: 76 Suppl 3 Topics: Adult; Antineoplastic Agents; Busulfan; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Immunolo	1991

Article	Year
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood, 2022, 05-12, Volume: 139, Issue:19 Topics: Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Polycythemia Vera; Thrombocythemia, Esse	2022
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood, 2022, 05-12, Volume: 139, Issue:19 Topics: Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Polycythemia Vera; Thrombocythemia, Esse	2022
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood, 2022, 05-12, Volume: 139, Issue:19 Topics: Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Polycythemia Vera; Thrombocythemia, Esse	2022
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood, 2022, 05-12, Volume: 139, Issue:19 Topics: Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Polycythemia Vera; Thrombocythemia, Esse	2022
Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 12-01, Volume: 36, Issue:34 Topics: Adult; Aspirin; Australia; Disease Progression; Dose-Response Relationship, Drug; Drug Administratio	2018
Thromboembolic events in polycythemia vera. Annals of hematology, 2019, Volume: 98, Issue:5 Topics: Age Factors; Anticoagulants; Aspirin; Humans; Hydroxyurea; Interferons; Nitriles; Phlebotomy; Polycy	2019
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Annals of hematology, 2014, Volume: 93, Issue:12 Topics: Aged; Aged, 80 and over; Alkylating Agents; Blood Cell Count; Busulfan; Comorbidity; Disease Progres	2014
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jun-20, Volume: 27, Issue:18 Topics: Biomarkers; Bone Marrow; Hemoglobins; Hemorrhage; Humans; Hydroxyurea; Leukocyte Count; Platelet Agg	2009
Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results. International journal of hematology, 2009, Volume: 90, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Aging; Blood Platelets; Cardiovascular Diseases; Clinical Protocols;	2009
The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2009, Volume: 20, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Cell Com	2009
Cardiovascular events and intensity of treatment in polycythemia vera. The New England journal of medicine, 2013, Jan-03, Volume: 368, Issue:1 Topics: Aged; Antineoplastic Agents; Cardiovascular Diseases; Combined Modality Therapy; Female; Follow-Up S	2013
Cardiovascular events and intensity of treatment in polycythemia vera. The New England journal of medicine, 2013, Jan-03, Volume: 368, Issue:1 Topics: Aged; Antineoplastic Agents; Cardiovascular Diseases; Combined Modality Therapy; Female; Follow-Up S	2013
Cardiovascular events and intensity of treatment in polycythemia vera. The New England journal of medicine, 2013, Jan-03, Volume: 368, Issue:1 Topics: Aged; Antineoplastic Agents; Cardiovascular Diseases; Combined Modality Therapy; Female; Follow-Up S	2013
Cardiovascular events and intensity of treatment in polycythemia vera. The New England journal of medicine, 2013, Jan-03, Volume: 368, Issue:1 Topics: Aged; Antineoplastic Agents; Cardiovascular Diseases; Combined Modality Therapy; Female; Follow-Up S	2013
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; F	2005
Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia. Acta haematologica, 2007, Volume: 118, Issue:4 Topics: Adult; Aged; Antithrombin III; Aspirin; Drug Therapy, Combination; Female; Fibrin Fibrinogen Degrada	2007
Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 1999, Volume: 5, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Disease-Free Survival; Female; Hemorr	1999
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. British journal of haematology, 2000, Volume: 110, Issue:3 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busul	2000
Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Seminars in hematology, 1986, Volume: 23, Issue:2 Topics: Acute Disease; Age Factors; Bloodletting; Chlorambucil; Combined Modality Therapy; False Positive Re	1986

Article	Year
A Case of Thrombotic Vasculopathy in the Setting of High-Dose Hydroxyurea Use. Wounds : a compendium of clinical research and practice, 2021, Volume: 33, Issue:12 Topics: Aged; Debridement; Drug Eruptions; Humans; Hydroxyurea; Male; Skin; Thrombosis	2021
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. Cancer, 2022, 07-01, Volume: 128, Issue:13 Topics: Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Nitriles; Poly	2022
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients. Leukemia, 2022, Volume: 36, Issue:10 Topics: Humans; Hydroxyurea; Janus Kinase Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Thrombocythe	2022
Machine learning analyses constructed a novel model to predict recurrent thrombosis in adults with essential thrombocythemia. Journal of thrombosis and thrombolysis, 2023, Volume: 56, Issue:2 Topics: Adult; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Risk Factors; Thrombocythemia, Essentia	2023
Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China. Annals of hematology, 2023, Volume: 102, Issue:8 Topics: Aged; Calreticulin; Humans; Hydroxyurea; Janus Kinase 2; Mutation; Retrospective Studies; Thrombocyt	2023
Moving toward disease modification in polycythemia vera. Blood, 2023, Nov-30, Volume: 142, Issue:22 Topics: Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Leukemia, Myeloid, Acute; Polycythemia Vera;	2023
Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin. European journal of haematology, 2020, Volume: 105, Issue:4 Topics: Aspirin; Drug Therapy, Combination; Health Care Surveys; Humans; Hungary; Hydroxyurea; Quinazolines;	2020
[Recent advances in polycythemia vera treatment]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2020, Volume: 61, Issue:9 Topics: Aspirin; Clinical Trials as Topic; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Polycythem	2020
Multiple aortic thrombi in essential thrombocythaemia. British journal of haematology, 2021, Volume: 193, Issue:5 Topics: Aged; Aorta, Abdominal; Aspirin; Cefazolin; Echocardiography; Heparin; Humans; Hydroxyurea; Male; St	2021
Management of hydroxyurea resistant or intolerant polycythemia vera. Leukemia & lymphoma, 2021, Volume: 62, Issue:10 Topics: Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Phlebotomy; Polycythemia Vera; Thrombosis	2021
Hemorrhage and Infarction of the Conjunctiva and Orbit in Essential Thrombocythemia. The Journal of craniofacial surgery, 2017, Volume: 28, Issue:3 Topics: Aged, 80 and over; Biopsy; Conjunctiva; Eye Hemorrhage; Female; Hematologic Agents; Humans; Hydroxyu	2017
New guidelines from the NCCN for polycythemia vera. Clinical advances in hematology & oncology : H&O, 2017, Volume: 15, Issue:11 Topics: Antineoplastic Agents; Cytoreduction Surgical Procedures; Disease Management; Humans; Hydroxyurea; N	2017
Vascular endothelial cell expression of JAK2 Haematologica, 2019, Volume: 104, Issue:1 Topics: Animals; Disease Models, Animal; Endothelial Cells; Gene Expression Regulation, Enzymologic; Humans;	2019
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. American journal of hematology, 2019, Volume: 94, Issue:1 Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans;	2019
Effects of polymorphic DNA genes involved in BER and caspase pathways on the clinical outcome of myeloproliferative neoplasms under treatment with hydroxyurea. Molecular medicine reports, 2018, Volume: 18, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Caspases; DNA Repair; Female; Humans; Hydroxyurea; Janus	2018
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. Blood cancer journal, 2018, 11-12, Volume: 8, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Hydroxyurea; Incidence; Male; Middle Aged; Myeloprol	2018
Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera. Blood cancer journal, 2018, 11-26, Volume: 8, Issue:12 Topics: Humans; Hydroxyurea; Incidence; Phlebotomy; Polycythemia Vera; Thrombosis; Treatment Outcome; Venous	2018
Management of an adult patient with sickle cell disease and acute chest syndrome by veno-venous extracorporeal membrane oxygenation. Annals of hematology, 2019, Volume: 98, Issue:3 Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Anticoagulants; Combined Modality Therapy; Dobutamine; Ex	2019
Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. Journal of the National Comprehensive Cancer Network : JNCCN, 2019, 03-01, Volume: 17, Issue:3 Topics: Aged; Aged, 80 and over; Female; Health Care Surveys; Humans; Hydroxyurea; Kaplan-Meier Estimate; Ma	2019
Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis. Annals of hematology, 2019, Volume: 98, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Drug Resistance; Female; Fever; Follow-Up Studies; Humans; Hydroxyur	2019
Treatment target in polycythemia vera. The New England journal of medicine, 2013, 04-18, Volume: 368, Issue:16 Topics: Antineoplastic Agents; Cardiovascular Diseases; Female; Hematocrit; Humans; Hydroxyurea; Male; Phleb	2013
Treatment target in polycythemia vera. The New England journal of medicine, 2013, 04-18, Volume: 368, Issue:16 Topics: Antineoplastic Agents; Cardiovascular Diseases; Female; Hematocrit; Humans; Hydroxyurea; Male; Phleb	2013
Treatment target in polycythemia vera. The New England journal of medicine, 2013, 04-18, Volume: 368, Issue:16 Topics: Antineoplastic Agents; Cardiovascular Diseases; Female; Hematocrit; Humans; Hydroxyurea; Male; Phleb	2013
Treatment target in polycythemia vera. The New England journal of medicine, 2013, 04-18, Volume: 368, Issue:16 Topics: Antineoplastic Agents; Cardiovascular Diseases; Female; Hematocrit; Humans; Hydroxyurea; Male; Phleb	2013
Treatment target in polycythemia vera. The New England journal of medicine, 2013, 04-18, Volume: 368, Issue:16 Topics: Antineoplastic Agents; Cardiovascular Diseases; Female; Hematocrit; Humans; Hydroxyurea; Male; Phleb	2013
Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea. Leukemia & lymphoma, 2014, Volume: 55, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myeloid, Chro	2014
Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide. Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13 Suppl 2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hydr	2013
Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:4 Topics: Adult; Aged; Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Janus Kinase 2; Male	2014
The thrombotic events in polycythemia vera patients may be related to increased oxidative stress. Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2014, Volume: 23, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Aspirin; Body Mass Index; Bone Marrow; Case-Control St	2014
Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications. Blood cells, molecules & diseases, 2014, Volume: 53, Issue:4 Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Blood Vessels; Case-Control	2014
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. American journal of hematology, 2015, Volume: 90, Issue:5 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Austria; Female; H	2015
Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. Thrombosis research, 2015, Volume: 135, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Blood Cell Count; Comorbidity; Databases, Factual;	2015
New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera. American journal of hematology, 2015, Volume: 90, Issue:8 Topics: Age Factors; Aged; Aspirin; Drug Administration Schedule; Enzyme Inhibitors; Fibrinolytic Agents; Hu	2015
Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. Turkish journal of haematology : official journal of Turkish Society of Haematology, 2017, Mar-01, Volume: 34, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Chronic Disease; Fe	2017
Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea. Leukemia & lymphoma, 2017, Volume: 58, Issue:1 Topics: Antineoplastic Agents, Alkylating; Busulfan; Drug Resistance, Neoplasm; Drug Tolerance; Female; Foll	2017
Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin. European journal of haematology, 2017, Volume: 98, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Human	2017
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematologica, 2017, Volume: 102, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Cell Count; Combined Modality Therapy; Drug Resist	2017
Can pegylated interferon improve the outcome of polycythemia vera patients? Journal of hematology & oncology, 2017, 01-13, Volume: 10, Issue:1 Topics: Adolescent; Adult; Aged; Disease Progression; Female; Humans; Hydroxyurea; Interferon-alpha; Janus K	2017
Thrombotic complications of polycythemia vera. Hematology (Amsterdam, Netherlands), 2008, Volume: 13, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Erythrocyte Count; Female; Hemoglobins; Humans	2008
Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. Annals of hematology, 2009, Volume: 88, Issue:10 Topics: Aged; Female; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Neg	2009
Treatment outcome in a cohort of young patients with polycythemia vera. Internal and emergency medicine, 2010, Volume: 5, Issue:5 Topics: Adult; Antineoplastic Agents; Aspirin; Cohort Studies; Combined Modality Therapy; Disease Progressio	2010
Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia. Internal medicine journal, 2011, Volume: 41, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Colony-Forming Units Assay; DNA Mutational Analysis; Erythroid Precu	2011
Non-ST-segment elevation myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor: a case report. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2011, Volume: 17, Issue:5 Topics: Electrocardiography; Enzyme Inhibitors; Humans; Hydroxyurea; Male; Middle Aged; Myocardial Infarctio	2011
Red cells playing as activated platelets in thalassemia intermedia. Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:10 Topics: Aspirin; beta-Thalassemia; Blood Platelets; Erythrocytes; Hematology; Hemoglobins; Humans; Hydroxyur	2010
Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. British journal of haematology, 2011, Volume: 152, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Evaluation; Drug Resistance; Epidemiologic Methods;	2011
Treatment related changes in antifibrinolytic activity in patients with polycythemia vera. Hematology (Amsterdam, Netherlands), 2010, Volume: 15, Issue:6 Topics: Adult; Aged; alpha-2-Antiplasmin; Biomarkers; Carboxypeptidase B2; Case-Control Studies; Female; Fib	2010
JAK inhibition in myelofibrosis. The New England journal of medicine, 2010, 12-16, Volume: 363, Issue:25 Topics: Humans; Hydroxyurea; Janus Kinase 1; Janus Kinase 2; Mutation; Nitriles; Palliative Care; Primary My	2010
Long-term follow-up of liver transplantation for Budd-Chiari syndrome with antithrombotic therapy based on the etiology. Transplantation, 2011, Aug-15, Volume: 92, Issue:3 Topics: Adolescent; Adult; Anticoagulants; Aspirin; Budd-Chiari Syndrome; Child; Female; Fibrinolytic Agents	2011
Anticoagulant-resistant thrombophilia in a patient with polycythemia vera: a case report. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2011, Volume: 22, Issue:8 Topics: Aged; Anticoagulants; Aspirin; Factor Xa; Factor Xa Inhibitors; Fatal Outcome; Heparin, Low-Molecula	2011
In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology. The Journal of clinical investigation, 2012, Volume: 122, Issue:1 Topics: Anemia, Sickle Cell; Eptifibatide; Hematologic Diseases; Hemolytic-Uremic Syndrome; Hemorheology; Hu	2012
How to manage children and young adults with myeloproliferative neoplasms. Leukemia, 2012, Volume: 26, Issue:7 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antiviral Agents;	2012
Cerebral infarct in a patient with a history of systemic arterial and venous thrombosis from essential thrombocythemia. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2012, Volume: 21, Issue:8 Topics: Arterial Occlusive Diseases; Biopsy; Bone Marrow Examination; Cerebral Angiography; Cerebral Infarct	2012
Polycythemia vera, the hematocrit, and blood-volume physiology. The New England journal of medicine, 2013, Jan-03, Volume: 368, Issue:1 Topics: Antineoplastic Agents; Cardiovascular Diseases; Female; Hematocrit; Humans; Hydroxyurea; Male; Phleb	2013
Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood, 2003, May-01, Volume: 101, Issue:9 Topics: Adolescent; Adult; Anemia; Cohort Studies; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Incid	2003
When and how to treat essential thrombocythemia. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxyurea; Leukemia	2005
Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica, 2008, Volume: 93, Issue:3 Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans;	2008
Acute myocardial infarction: an unusual presentation of essential thrombocytosis in a 17-year-old man. Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:2 Topics: Adolescent; Female; Humans; Hydroxyurea; Myocardial Infarction; Nucleic Acid Synthesis Inhibitors; P	2008
Treatment of polycythemia vera with hydroxyurea. American journal of hematology, 1984, Volume: 17, Issue:4 Topics: Acute Disease; Aged; Bone Marrow; Female; Humans; Hydroxyurea; Leukemia; Leukopenia; Male; Middle Ag	1984
Hydroxyurea in essential thrombocytosis. The New England journal of medicine, 1995, Sep-21, Volume: 333, Issue:12 Topics: Aspirin; Follow-Up Studies; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Thrombocytosis; Th	1995
Hydroxyurea in essential thrombocytosis. The New England journal of medicine, 1995, Sep-21, Volume: 333, Issue:12 Topics: Humans; Hydroxyurea; Thrombocytosis; Thrombosis	1995
Hydroxyurea in essential thrombocytosis. The New England journal of medicine, 1995, Sep-21, Volume: 333, Issue:12 Topics: Data Interpretation, Statistical; Humans; Hydroxyurea; Multivariate Analysis; Recurrence; Thrombocyt	1995
APC resistance as an additional thrombotic risk factor in a patient suffering from polycythemia vera and recurrent thrombosis. Annals of hematology, 1997, Volume: 74, Issue:1 Topics: Drug Resistance; Enzyme Activation; Factor V; Hematopoiesis; Heterozygote; Humans; Hydroxyurea; Male	1997
The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link? Seminars in thrombosis and hemostasis, 1997, Volume: 23, Issue:4 Topics: Aged; Alkylating Agents; Aspirin; Erythromelalgia; Female; Fibrinolytic Agents; Hemorrhage; Hemorrha	1997
The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera. European journal of haematology, 1999, Volume: 62, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Busulfan; Drug Tolerance; Erysipelas; Erythropoiesis; Female; Hemato	1999
Medical management of a large aortic thrombus in a young woman with essential thrombocythemia. Mayo Clinic proceedings, 2001, Volume: 76, Issue:4 Topics: Aorta, Abdominal; Aortic Diseases; Aspirin; Biopsy, Needle; Drug Therapy, Combination; Female; Follo	2001
Prevention of recurrent thrombosis following liver transplantation for Budd-Chiari syndrome associated with myeloproliferative disorders: treatment with hydroxyurea and aspirin. Transplantation proceedings, 1991, Volume: 23, Issue:1 Pt 2 Topics: Adult; Aspirin; Budd-Chiari Syndrome; Female; Humans; Hydroxyurea; Liver Transplantation; Male; Myel	1991
Long-term management of polycythemia vera with hydroxyurea: a progress report. Seminars in hematology, 1986, Volume: 23, Issue:3 Topics: Drug Administration Schedule; Humans; Hydroxyurea; Leukemia; Polycythemia Vera; Thrombosis	1986
[A new etiology of inflammatory livedo: thrombocytosis]. La Presse medicale, 1969, Jan-18, Volume: 77, Issue:3 Topics: Arteritis; Busulfan; Diagnosis, Differential; Erythromelalgia; Female; Foot Dermatoses; Humans; Hydr	1969
Hydroxyurea: a radiosensitizer in the treatment of neoplasms of the head and neck. The American journal of roentgenology, radium therapy, and nuclear medicine, 1969, Volume: 105, Issue:3 Topics: Adult; Age Factors; Aged; Female; Gastrointestinal Diseases; Head; Head and Neck Neoplasms; Hematolo	1969

hydroxyurea and Blood Clot